JACKSONVILLE, Fla., March 8, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2016.
Reserve Your Seat: Register Today
The event will be webcast live via the Internet on:
March 14, 2017
4:30 PM ET
Click here to register today, or visit http://tapimmune.com/register/.
Day-of Call-in Information:
To access the live conference call on March 14, 2017, at 4:30pm ET you may use:
- (877) 870-4263 (U.S.)
- (412) 317-0790 (International)
To access the live audio webcast, visit the Events section of the TapImmune website http://tapimmune.com/events/. The webcast will also be archived for 90 days beginning at approximately 6:30 p.m. ET, on March 14, 2017.
About TapImmune, Inc.
TapImmune, Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
For additional information about TapImmune, please visit the Company's website at http://tapimmune.com. Join the Company's email list at http://tapimmune.com/investors/email-alerts/.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-host-inaugural-quarterly-business-update-conference-call-and-webcast-300419828.html
SOURCE TapImmune, Inc.
